BRPI0415525A - derivados de imidazola e seu uso como agentes farmacêuticos - Google Patents

derivados de imidazola e seu uso como agentes farmacêuticos

Info

Publication number
BRPI0415525A
BRPI0415525A BRPI0415525-4A BRPI0415525A BRPI0415525A BR PI0415525 A BRPI0415525 A BR PI0415525A BR PI0415525 A BRPI0415525 A BR PI0415525A BR PI0415525 A BRPI0415525 A BR PI0415525A
Authority
BR
Brazil
Prior art keywords
pharmaceutical agents
imidazole derivatives
cancer
compounds
treatment
Prior art date
Application number
BRPI0415525-4A
Other languages
English (en)
Inventor
Konrad Honold
Stefan Scheiblich
Thomas Von Hirschheydt
Edgar Voss
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0415525A publication Critical patent/BRPI0415525A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"DERIVADOS DE IMIDAZOLA E SEU USO COMO AGENTES FARMACêUTICOS". Compostos da fórmula geral (I): são produtos terapêuticos valiosos para o tratamento de câncer e doenças relacionadas ao câncer.
BRPI0415525-4A 2003-10-17 2004-10-15 derivados de imidazola e seu uso como agentes farmacêuticos BRPI0415525A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03023677 2003-10-17
PCT/EP2004/011598 WO2005040154A1 (en) 2003-10-17 2004-10-15 Novel imidazole derivatives and their use as pharmaceutical agents

Publications (1)

Publication Number Publication Date
BRPI0415525A true BRPI0415525A (pt) 2006-12-26

Family

ID=34486074

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415525-4A BRPI0415525A (pt) 2003-10-17 2004-10-15 derivados de imidazola e seu uso como agentes farmacêuticos

Country Status (16)

Country Link
US (1) US7169781B2 (pt)
EP (1) EP1678163B1 (pt)
JP (1) JP2007508344A (pt)
KR (1) KR100796971B1 (pt)
CN (1) CN1867563A (pt)
AR (1) AR046286A1 (pt)
AT (1) ATE420084T1 (pt)
AU (1) AU2004283845A1 (pt)
BR (1) BRPI0415525A (pt)
CA (1) CA2538134A1 (pt)
DE (1) DE602004018962D1 (pt)
ES (1) ES2317030T3 (pt)
MX (1) MXPA06003698A (pt)
RU (1) RU2006116628A (pt)
TW (1) TW200528447A (pt)
WO (1) WO2005040154A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI377198B (en) 2005-08-24 2012-11-21 Eisai R&D Man Co Ltd Novel pyridine derivatives and pyrimidine derivatives (3)
RU2008141761A (ru) 2006-03-22 2010-04-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) ИНГИБИТОРЫ с-МЕТ ПРОТЕИНКИНАЗЫ
EP2040546A4 (en) * 2006-06-22 2009-12-23 Merck & Co Inc tyrosine kinase inhibitor
US7683060B2 (en) 2006-08-07 2010-03-23 Incyte Corporation Triazolotriazines as kinase inhibitors
CN101454311B (zh) 2006-08-23 2013-03-27 卫材R&D管理有限公司 苯氧基吡啶衍生物的盐和其结晶及其制备方法
US7790885B2 (en) 2006-08-31 2010-09-07 Eisai R&D Management Co., Ltd. Process for preparing phenoxypyridine derivatives
EP2222647B1 (en) 2006-10-23 2015-08-05 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
KR101532256B1 (ko) 2006-11-22 2015-06-29 인사이트 코포레이션 키나제 억제제로서의 이미다조트리아진 및 이미다조피리미딘
CN101679378A (zh) * 2007-05-02 2010-03-24 沃泰克斯药物股份有限公司 用作激酶抑制剂的噻唑和吡唑
AU2008257044A1 (en) * 2007-05-24 2008-12-04 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
DE602008005786D1 (de) 2007-10-03 2011-05-05 Vertex Pharma C-met-proteinkinasehemmer
JP2009132660A (ja) 2007-11-30 2009-06-18 Eisai R & D Management Co Ltd 食道癌治療用組成物
WO2009103032A1 (en) 2008-02-15 2009-08-20 Rigel Pharmaceuticals, Inc. Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases
WO2009143211A2 (en) 2008-05-21 2009-11-26 Incyte Corporation Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
EA025304B1 (ru) 2010-02-03 2016-12-30 Инсайт Холдингс Корпорейшн ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИНЫ В КАЧЕСТВЕ c-Met ИНГИБИТОРОВ
CA2880896C (en) 2012-06-26 2021-11-16 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
EA035349B1 (ru) 2012-11-21 2020-05-29 ПиТиСи ТЕРАПЬЮТИКС, ИНК. ЗАМЕЩЕННЫЕ ПИРИМИДИНОВЫЕ ОБРАТНЫЕ ИНГИБИТОРЫ Bmi-1
WO2015030847A1 (en) 2013-08-30 2015-03-05 Ptc Therapeutics, Inc. Substituted pyrimidine bmi-1 inhibitors
WO2015076800A1 (en) 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
KR102030886B1 (ko) * 2016-09-23 2019-10-10 재단법인 대구경북첨단의료산업진흥재단 신규한 이미다졸일 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
AU2019340402B2 (en) 2018-08-17 2025-04-03 Ptc Therapeutics, Inc. Method for treating pancreatic cancer
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
MX2022001940A (es) 2019-08-14 2022-05-10 Incyte Corp Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2.
CN119930610A (zh) 2019-10-11 2025-05-06 因赛特公司 作为cdk2抑制剂的双环胺
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656644A (en) 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
JPH10510281A (ja) 1994-12-13 1998-10-06 エフ・ホフマン−ラ ロシュ アーゲー イミダゾール誘導体
AU8154998A (en) * 1997-06-19 1999-01-04 Smithkline Beecham Corporation Novel aryloxy substituted pyrimidine imidazole compounds
US6790852B2 (en) 2002-04-18 2004-09-14 Hoffmann-La Roche Inc. 2-(2,6-dichlorophenyl)-diarylimidazoles

Also Published As

Publication number Publication date
US20050113342A1 (en) 2005-05-26
KR20060063985A (ko) 2006-06-12
KR100796971B1 (ko) 2008-01-22
US7169781B2 (en) 2007-01-30
RU2006116628A (ru) 2007-11-27
CA2538134A1 (en) 2005-05-06
JP2007508344A (ja) 2007-04-05
ES2317030T3 (es) 2009-04-16
ATE420084T1 (de) 2009-01-15
TW200528447A (en) 2005-09-01
CN1867563A (zh) 2006-11-22
EP1678163B1 (en) 2009-01-07
AU2004283845A1 (en) 2005-05-06
AR046286A1 (es) 2005-11-30
WO2005040154A1 (en) 2005-05-06
EP1678163A1 (en) 2006-07-12
DE602004018962D1 (de) 2009-02-26
MXPA06003698A (es) 2006-06-05

Similar Documents

Publication Publication Date Title
BRPI0415525A (pt) derivados de imidazola e seu uso como agentes farmacêuticos
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
GB0022438D0 (en) Organic Compounds
MXPA05012573A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de cinasa.
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
MXPA05011076A (es) Derivados de quinazolina para el tratamiento de cancer.
CY1109728T1 (el) Νεα παραγωγα υδαντοϊνης για τη θεραπεια αποφρακτικων νοσηματων της αναπνευστικης οδου
BR0309355A (pt) 2-(2,6-diclorofenil)-diarilimidazóis
BRPI0418251B8 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
SE0301700D0 (sv) Novel compounds
BR0008365A (pt) 2-amino-6-anilino-purinas e o seu uso comomedicamento
ATE408601T1 (de) Fredericamycin-derivate
ATE514699T1 (de) Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
BRPI0412343A (pt) derivados de piridazina e seu uso como agentes terapêuticos
IL127965A0 (en) Pentafluorobenzenesulfonamide derivatives analogs thereof and pharmaceutical compositions containing the same
HN2004000232A (es) " derivados de pirrolo(3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden."
DE602004014163D1 (de) Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
TW200505452A (en) Chemical compounds
BR0209645A (pt) Oxazolo- e furopirimidinas e seu uso como medicamentos
ATE302203T1 (de) Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
NO20043792L (no) New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine
ECSP066767A (es) Derivados 1h-tieno[2,3-c]pirazol útiles como inhibidores de quinasa
BR0311491A (pt) Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero
ATE482955T1 (de) Azabicyclooctan-3-onderivate und deren verwendung

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.